The following is a listing of myeloma treatments associated with this tag.
View all treatments in development for myeloma patients around the US.
Tinostamustine
Tinostamustine (formerly EDO-S101) is a first-in-class fusion molecule combining vorinostat (a histone-deacetylase inhibitor) and bendamustine (an alkylating chemotherapy agent).
SparkCures Verified Accurate, up-to-date information. Learn more
The following is a listing of treatments in development for patients with multiple myeloma who have received one to two prior lines of therapy.
Tinostamustine
Tinostamustine (formerly EDO-S101) is a first-in-class fusion molecule combining vorinostat (a histone-deacetylase inhibitor) and bendamustine (an alkylating chemotherapy agent).
SparkCures Verified Accurate, up-to-date information. Learn more
The following is a listing of treatments in development for patients with multiple myeloma who have received three or more prior lines of therapy.
Tinostamustine
Tinostamustine (formerly EDO-S101) is a first-in-class fusion molecule combining vorinostat (a histone-deacetylase inhibitor) and bendamustine (an alkylating chemotherapy agent).
SparkCures Verified Accurate, up-to-date information. Learn more
The following is a listing of myeloma clinical trials associated with this tag.
View all active clinical trials around the US.